Rahim Suleman

Rahim Suleman from H.C.W. asked about the expected commercial infrastructure size and scope for Imsidolimab, assuming timely approval. He also inquired about planned direct-to-consumer campaigns for Fanapt and Bysanti in 2026, the commercial availability timeline for Nereus, the regulatory outlook for tradipitant in gastroparesis, and the enrollment timeline for the tradipitant GLP-1 phase 3 trial. Finally, he asked about the anticipated completion of enrollment for the iloperidone LAI phase 3 program.

Answer

Dr. Mihael Polymeropoulos, CEO of Vanda Pharmaceuticals Inc., stated that Imsidolimab would likely be supported by a small, dedicated specialty sales force targeting dermatologists. He mentioned that current DTC campaigns focus on Vanda's brand, Fanapt, and Ponvory, with no concrete Bysanti campaign plans yet. Nereus commercial materials are expected by late Q2 or early Q3. For gastroparesis, Vanda is preparing for an FDA hearing. The tradipitant GLP-1 phase 3 study could yield results by late Q3/Q4. He noted that iloperidone LAI enrollment is ongoing but slower than desired due to European study delays, making year-end recruitment goals uncertain.